<DOC>
	<DOCNO>NCT00262821</DOCNO>
	<brief_summary>This randomized phase III trial study cisplatin , radiation therapy , tirapazamine see well work compare cisplatin radiation therapy treat patient cervical cancer . Drugs use chemotherapy , cisplatin tirapazamine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Internal radiation use radioactive material place directly near tumor kill tumor cell . Cisplatin tirapazamine may make tumor cell sensitive radiation therapy . It yet know whether give cisplatin together radiation therapy effective without tirapazamine treat cervical cancer .</brief_summary>
	<brief_title>Cisplatin Radiation Therapy With Without Tirapazamine Treating Patients With Cervical Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Compare progression-free survival patient stage IB , IIA , IIB , IIIB , IVA carcinoma cervix treat cisplatin radiotherapy v without tirapazamine . SECONDARY OBJECTIVES : I . Compare overall survival patient treat regimen . II . Compare toxicity regimens patient . TERTIARY OBJECTIVES : I. Correlate study treatment tumor expression carbonic anhydrase IX ( CA-IX ) recurrence-free survival , overall survival , metastasis patient treat regimen . II . Correlate expression CA-IX , hypoxia inducible factor-1α , CD-31 , thrombospondin-1 , CD-105 , vascular endothelial growth factor ( VEGF ) primary tumor tissue recurrence-free survival , overall survival , metastasis patient treat regimen . III . Correlate pre-treatment and/or post-treatment serum concentration angiogenic marker include angiogenin VEGF recurrence-free survival , overall survival , metastasis patient treat regimen . IV . Correlate various combination biological marker hypoxia angiogenesis recurrence-free survival , overall survival , metastasis patient treat regimen . V. Correlate level individual biological marker hypoxia angiogenesis clinicopathological characteristic include tumor size , histologic subtype , FIGO stage , depth invasion , pelvic node status , site recurrence , hemoglobin level well patient , age , race performance status patient treat regimen . OUTLINE : This randomize , control , multicenter study . Patients stratify accord FIGO stage disease ( IB2 vs IIA v IIB v IIIB v IVA ) , brachytherapy method ( low-dose rate v high-dose rate ) , surgical stag para-aortic node ( yes v ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive cisplatin IV 30-60 minute weekly day 1 , 8 , 15 , 22 , 29 , 36 ( week 1-6 ) . Patients also undergo external beam radiotherapy pelvis daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 ( week 1-5 ) . Patients receive either 1 2 application low-dose rate brachytherapy week 6-8 OR 5 application high-dose rate ( HDR ) * brachytherapy weekly week 4-8 3-5 day parametrial boost radiotherapy** begin first brachytherapy implant . Treatment continue absence disease progression unacceptable toxicity . ARM II : Patients receive tirapazamine IV 2 hour day 1 , 8 , 10 , 12 , 15 , 22 , 24 , 26 , 29 cisplatin IV 1 hour day 1 , 15 , 29 . Patients also undergo radiotherapy brachytherapy arm I . Treatment continue absence disease progression unacceptable toxicity . NOTE : *No external beam radiotherapy administer day HDR brachytherapy . If majority external beam radiotherapy administer , HDR brachytherapy may administer 2 application per week ( separate least 72 hour ) order complete treatment within 8 week . NOTE : ** Patients may receive parametrial boost discretion treat radiation oncologist . After completion study treatment , patient follow least 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm invasive squamous cell carcinoma , adenocarcinoma , adenosquamous cell carcinoma uterine cervix Stage IB2 , IIA , IIB , IIIB , IVA disease Stage IIA tumor must &gt; 4 cm Primary , untreated disease Negative , nonsuspicious paraaortic node lymphangiogram , CT scan , MRI , lymphadenectomy Must adequately clinically stag Suitable treatment radical intent use concurrent chemotherapy pelvic radiotherapy No disease involvement low third vagina regardless stage ( stage IIIA , IIIB IVA low onethird involvement ) No carcinoma cervical stump Performance status GOG 03 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT ≤ 3 time ULN Alkaline phosphatase ≤ 3 time ULN Creatinine ≤ ULN calculate creatinine clearance ≥ 60mL/min No New York Heart Association class IIIIV heart failure No history myocardial infarction No unstable angina No uncontrolled hypertension No pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No septicemia severe infection No invasive malignancy within past 5 year except nonmelanoma skin cancer No prior hysterectomy plan hysterectomy part initial cervix cancer therapy No prior coronary artery bypass surgery No prior cancer therapy would preclude study treatment No concurrent angina medication No concurrent intensitymodulated radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>